Ronen Tsimerman was named Chief Financial Officer of Lifeward Ltd., effective November 1, 2026. As of November 6, 2026, Lifeward Ltd. has reported 6 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 23, 2026 to October 27, 2026, naming 5 appointments and 3 departures (Form 8-K, October 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lifeward Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Ronen Tsimerman · Role: Chief Financial Officer · Effective: 2026-11-01 · 8-K, 2026-10-27
- · In / out: In · Person: Josh Hexter · Role: Chief Executive Officer · Effective: 2026-10-01 · 8-K, 2026-10-01
- · In / out: Out · Person: Mark Grant · Role: President and Chief Executive Officer · Effective: 2026-08-31 · 8-K, 2026-08-31
- · In / out: In · Person: Yonason Greenwald · 8-K, 2026-08-20
- · In / out: Out · Person: Almog Adar · Role: Chief Financial Officer · 8-K, 2026-08-14
Lifeward Ltd. reported changes in 6 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-23 to 2026-10-27. They name 7 people, with 5 appointments and 3 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Lifeward Ltd. files it.
Also on the record for Lifeward Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 8, 2026 | Form D, private offering | $11.16M sold | Form D page | Source |
| May 14, 2026 | Stake report, Schedule 13D, by Oramed Pharmaceuticals Inc. | 49.9% of the class | 5%+ stakes | Source |
| April 2, 2026 | Form D, private offering | $20M sold | Form D page | Source |
| March 25, 2026 | Acquired Oratech Ltd. | — | Acquisition | Source |
| July 1, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| June 26, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| June 25, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 20, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 14, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 11, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| January 13, 2025 | Form D, private offering | $5M sold | Form D page | Source |
Selling to them or working with them? See who runs Lifeward Ltd. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lifeward Ltd. and the records around it.
Lifeward Ltd. elsewhere on the record
- Company profile and every filing Jul 2026
- Form D filing Jul 2026
- 5%+ stake filings May 2026
- Form D filing Apr 2026
- Acquisition Mar 2026
- IPO filing Jun 2025
- Who owns it
Companies that share a holder
- Oramed Pharmaceuticals Inc. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Jul 2026), Scilex Holding Co (Feb 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Lifeward Ltd.
Get an email when Lifeward Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lifeward Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lifeward Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lifeward Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | In | Chief Financial Officer | 2026-11-01 | 8-K, 2026-10-27 | |
| 2026-10-01 | In | Chief Executive Officer | 2026-10-01 | 8-K, 2026-10-01 | |
| 2026-08-31 | Out | President and Chief Executive Officer | 2026-08-31 | 8-K, 2026-08-31 | |
| 2026-08-31 | In | Chief Executive Officer | 2026-09-01 | 8-K, 2026-08-31 | |
| 2026-08-20 | In | 8-K, 2026-08-20 | |||
| 2026-08-20 | In | 8-K, 2026-08-20 | |||
| 2026-08-20 | Out | 8-K, 2026-08-20 | |||
| 2026-08-14 | Out | Chief Financial Officer | 8-K, 2026-08-14 | ||
| 2026-04-23 | Reported | not named in the filing | 8-K, 2026-04-23 |
Who leads Lifeward Ltd., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Ronen Tsimerman, appointed, effective 2026-11-01 (filed 2026-10-27).
- Chief Executive Officer: Josh Hexter, appointed, effective 2026-10-01 (filed 2026-10-01).
- President and Chief Executive Officer: Mark Grant, departure reported, effective 2026-08-31 (filed 2026-08-31). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Lifeward Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Lifeward Ltd. (free up to 3)
Find people with the same kind of experience as the Chief Financial Officer at Lifeward Ltd., with the record behind each one.
Find candidates like Chief Financial Officer at Lifeward Ltd.Every change, in the filing's words
Appointed: Ronen Tsimerman, Chief Financial Officer, effective 2026-11-01
On October 26, 2026, the Board of Directors (the "Board") of Lifeward Ltd. (the "Company") appointed Ronen Tsimerman, age 56, as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective November 1, 2026.
- Mr. Tsimerman is an experienced global finance executive who most recently served as chief financial officer of Scopio Labs Ltd. from August through October 2026.
- Previously, he served as chief financial officer of IceCure Medical Ltd (Nasdaq: ICCM) from May 2017 to August 2026 and as its chief operating officer from May 2018 to November 2025.
- He served as chief financial officer of Insuline Medical Ltd. (TASE: INSL) from May 2015 to May 2017, as chief financial officer of Mer-Group Broadband division (TASE: CMER) from 2005 to 2013, and as vice president of finance of Mer-Group Telecom Division from 2013 to 2014.
- Mr. Tsimerman received a bachelor's degree in business and MBA from the College of Management, in Israel.
- The bonuses are subject to the terms of the Renewed Company's Compensation Policy and any required approvals.
- The CFO Employment Agreement provides for a 3-month notice period for termination, increasing to four months for either party following any change in the Company's Chief Executive Officer, including the appointment of a permanent Chief Executive Officer.
- In connection with his appointment, the Company also entered into its standard indemnification, insurance and exculpation agreement with Mr. Tsimerman.
Appointed: Josh Hexter, Chief Executive Officer, effective 2026-10-01
Effective October 1, 2026, the Company designated Josh Hexter, the Company's Interim Chief Executive Officer and principal executive officer, to also serve as the Company's interim principal financial officer and principal accounting officer.
- Mr. Hexter will not receive any additional compensation in connection with this designation.
Departing: Mark Grant, President and Chief Executive Officer, effective 2026-08-31
Effective August 31, 2026, Mr. Mark Grant will depart from his positions as the President and Chief Executive Officer of Lifeward Ltd. (the "Company") and as a member of the Company's Board of Directors (the "Board"), following the Company's entry into a separation agreement with Mr. Grant on August 31, 2026 (the "Separation Agreement").
Appointed: Josh Hexter, Chief Executive Officer, effective 2026-09-01
On August 31, 2026, the Board appointed Mr. Josh Hexter, age 56, as the Company's Interim Chief Executive Officer and principal executive officer, effective September 1, 2026.
- Mr. Grant's departure is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In connection with Mr. Grant's departure and to facilitate an orderly transition, effective September 1, 2026, the Company entered into a consulting agreement with Mr. Grant (the "Consulting Agreement" and, together with the Separation Agreement, the "Separation and Consulting Agreements").
- Pursuant to the Consulting Agreement, Mr. Grant will continue to support the Company as a Senior Advisor through September 30, 2026, providing transition assistance and other consulting services in exchange for a consulting fee of $40,000.
- Pursuant to the Separation Agreement, Mr. Grant's outstanding equity awards will cease vesting as of August 31, 2026, and any unvested equity awards will be forfeited as of such date.
- The Separation Agreement also contains customary mutual releases and provides for the continuation of certain confidentiality, restrictive covenant, indemnification and other obligations.
- Mr. Grant will not receive any cash severance payments or continued employee benefits in connection with his separation, other than compensation accrued through his separation date and the consulting fee described above.
Appointed: Yonason Greenwald
On August 14, 2026, the Board of Directors (the "Board") of Lifeward Ltd. (the "Company") appointed Yonason Greenwald and Haggai Zamir, each to serve as a Class III Director, with an initial term expiring at the Company's 2026 Annual Meeting of Shareholders.
Appointed: Avraham Gabay
On August 20, 2026, the Board appointed Avraham Gabay to serve as a Class III Director, with an initial term expiring at the Company's 2026 Annual Meeting of Shareholders.
Departing: Nadav Kidron
On August 20, 2026, Nadav Kidron notified the Board of his decision to step down from the Board, effective immediately.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
- Mr. Greenwald will serve as a member of each of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee and Mr. Zamir will serve as a member of the Nominating and Corporate Governance Committee.
- Mr. Gabay will also serve as Chair of the Board.
- As compensation for services as a director, each of Mr. Greenwald, Mr. Zamir and Mr. Gabay will be entitled to standard compensation available to non-employee directors of the Company as disclosed under "Director Compensation" in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 18, 2026.
- The departure of Mr. Kidron did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.
- The Company extends its deepest gratitude to Mr. Kidron for his distinguished service to the Board and lasting contributions to the Company.
Departing: Almog Adar, Chief Financial Officer
On August 14, 2026, the Company announced that Almog Adar will step down as the Chief Financial Officer of the Company.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
- Resignation of Directors On August 12, 2026, each of Robert J. Marshall, Jr., Michael Swinford and William Mark Sigsbee notified the Board of their decision to step down from the Board, effective as of August 13, 2026.
- The departure of each of Messrs. Marshall, Swinford and Sigsbee did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.
- The Company extends its deepest gratitude to each of Messrs. Marshall, Swinford and Sigsbee for their distinguished service to the Board and lasting contributions to the Company.
- Mr. Adar will continue to serve in his existing role through September 30, 2026 to assist with a transition to a successor.
- For purposes of the separation benefits under his existing employment agreement, as amended, Mr. Adar's departure will be treated as a termination without cause.
- On August 10, 2026, the Company entered into a separation agreement with Mr. Adar providing for separation benefits substantially similar to those contemplated by Mr. Adar's existing employment agreement.
Reported
Pursuant to notice provided on April 20, 2026, Jeannine Lynch's employment with Lifeward Ltd. (the "Company") as the Vice President of Strategy and Market Access will be terminated, effective May 3, 2026.
- Ms. Lynch's departure will be treated as a termination without cause pursuant to the terms of her Employment Agreement, dated July 9, 2021 (the "Employment Agreement").
- Ms. Lynch will receive severance and other benefits in accordance with the terms of her Employment Agreement.
- The terms of the Employment Agreement were disclosed in the Company's Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission on March 18, 2026.
Lifeward Ltd.'s funding history
Tools for this story
Each opens in a new tab, filled in for Lifeward Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.